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Abstract:
Background:
Current interventions in amyotrophic lateral sclerosis (ALS) are focused on supporting quality of life (QoL) and easing pain with a
multidisciplinary approach.
Objective:
Primary aim of this pilot work assessed feasibility, safety, tolerability and satisfaction of osteopathic manual treatment (OMT) in 14
ALS outpatients.
Methods:
Patients were randomized according to an initial single-blind design (12 weeks, T0-T1), in order to receive OMT (weekly for 4
weeks, and fortnightly for the following 8 weeks) versus usual-care (n=7 each group), followed by an OMT open period (T1-T2,
once  a  week for  8  weeks,  n=10).  Secondary  aims included blind osteopathic  assessment  of  somatic  dysfunctions  (SD) for  goal
attainment scale (GAS) calculation, Brief Pain Inventory-short form and McGill QoL-16 items.
Results:
OMT was demonstrated feasible and safe and patients displayed high satisfaction (T1-VAS=8.34 ± 0.46; T2-VAS=8.52 ± 0.60).
Considering secondary aims no significant differences emerged. Finally, at study entry (T0), a cervico-dorsal SD was found in 78%
of ALS patients versus 28% of healthy matched controls (p<0.01).
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Conclusion:
OMT was found feasible, safe and satisfactory in ALS. The lack of secondary aim differences can be due to the limited sample size.
OMT could be an interesting option to explore in ALS.
Keywords: Amyotrophic lateral sclerosis, Feasibility, Osteopathic manual treatment, Pilot trial.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive lack of strength,
muscle atrophy and spasticity. The disease usually leads to death in few months since symptom onset due to aspiration
pneumonia or respiratory dysfunction. Effective therapies for ALS are currently lacking and management guidelines
emphasize the role of a multidisciplinary approach in order to support an adequate quality of life (QoL); emphasis is
given on starting cares as soon as possible, providing them until  the  very end of life.  Furthermore, ALS  patients often
report pain that might easily go underrecognized and undertreated [1]. Among therapies used to face the progressive
lack of function in patients with ALS, kinesitherapy, is used in order to avoid excessive spasticity and deconditioning
that could overlap with the effects of the disease itself [2]. In this context, osteopathic manual treatment (OMT) might
be considered as a complementary approach to ALS, aiming to ameliorate pain management and QoL, as already shown
in other neurological disorders, such as Parkinson’s disease and headache [3, 4]. Although, to our best knowledge, no
literature report is available on OMT in ALS, there is pilot evidence of safety and efficacy of OMT in Parkinson’s
disease  (PD)  [3,  5].  Understanding  the  specific  impaired  or  altered  function  of  the  somatic  system  (somatic
dysfunctions, SD [6]) expressed by ALS patients might be useful for creating the basis for an effective OMT approach.
Finally, OMT is usually well tolerated with a low rate of side effects [4], albeit this has never been reported before in
vulnerable patients such as those affected by ALS.
The primary aim of this work consisted in assessing safety, feasibility, tolerability and satisfaction of OMT in a
preliminary series of ALS outpatients. The secondary aims included the blind assessment of pain and QoL, besides the
blind evaluation of the effects of the OMT by goal attainment scaling (GAS).
MATERIALS AND METHODOLOGY
Patients
Following approval of the protocol by the ethics committee, 14 consecutive ALS outpatients were recruited with
written  informed  consent.  All  clinical  investigation  were  conducted  according  to  the  principles  expressed  in  the
Declaration of Helsinki.
Inclusion criteria were: diagnosis of possible-, probable- or definite-ALS according to El Escorial criteria [7]; ALS
functional rating scale (ALSFRS-R) score >24; pulse oximetry values ≥92% in clinostatism. Exclusion criteria were:
presence of non-invasive ventilation (NIV) or tracheostomy; clinically relevant orthopnea or pulse oximetry values
<92% in clinostatism.
Clinical characterization of ALS included the ALSFRS-R [8], the ALS-severity scale (ALS-SS [9],) and the Norris
ALS scale [10]. The disease progression index (DPI) was estimated in this work as the loss of ALSFRS-R score over
time  since  onset:  [48  -  current  ALSFRS-R]/disease  duration  in  months  [11].  Finally,  14  age-  (±5  years)  and  sex-
matched healthy controls were also recruited among the caregivers just for comparison with ALS patients as regards the
initial osteopathic evaluation.
Interventions
Patients were randomized (time point: T0) by a randomly generated list according to an initial single-blind design,
followed by an open period (see below), in order to receive either OMT (n=7, OMT) or a standard-of-care treatment
(physiotherapy twice a week, n=7, FKT). OMT was administered once a week for the first four weeks, and fortnightly
for the following eight weeks. At the end of this period (T1), 10 patients received OMT (open period) once a week for
the following eight weeks (T2) (Fig. 1).
SD were defined as impaired or altered functions of components of the somatic system including skeletal, arthrodial
and myofascial structures, and their related vascular, lymphatic, and neural elements [6]. The osteopathic manoeuvres
applied in the OMT group were performed by 5-years experienced personnel and were individually tailored for each
patient, according to Greenman’s descriptions [12]. The OMT techniques were focused on the treatment of SD found
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during  the  re-evaluations  performed  before  each  session;  structural  (including  myofascial  release),  visceral,  and
craniosacral  techniques  were  performed  as  appropriate  [4].  Treatment  duration  was  always  40  minutes.
Outcome Measures
Primary:  Adverse effects of treatment, if reported by patients or caregivers, were recorded by a medical doctor
before starting each new session of OMT. A visual analogue scale (VAS) was included at T1 and T2 for those patients
receiving OMT, focusing on the perceived satisfaction regarding the treatment.
Secondary: Each patient was evaluated in blind by a clinical neurologist at the three time points (T0, T1 and T2) for
pain and QoL by using two dedicated questionnaires: the Brief Pain Inventory short form (BPI) and the McGill QoL (16
items). BPI allowed the calculation of the pain severity index (PSI) and the pain interference index (PII), averaging the
respective items of the scale [13]. The McGill QoL allowed the calculation of: total score (TS), single-item summary
score, macroareas scores: (a) physical or (b) psychological symptoms, (c) physical or (d) psychological well-being, and
(e) support [14].
Fig. (1). Gantt chart of the study. During the first study period (T0-T1), 7 ALS patients received OMT once a week (small white
blocks) for the first month and fortnightly during the following 8 weeks (big white blocks); during this period, 7 ALS patients were
followed according to usual care (FKT arm, black bar). During the second study period (T1-T2), 10 ALS patients received OMT on a
weekly basis.
Finally,  two  experienced  Doctors  of  Osteopathic  Medicine  (D.O.)  assessed  all  patients  (and  healthy  controls),
independently  and  blindly  with  respect  to  the  initial  treatment  allocation,  re-assessing  them  at  T1  and  T2.  The
observations of these two raters were not used for guiding treatments. The evaluation was performed according to a pre-
decided  structured  scheme  focusing  on  SD  in  order  to  check  the  same  anatomical  structures  and  qualify  specific
parameters (use of accessory muscles of breathing, direction of abdominal wall movement during inspiration, cervical
or  dorsal  kyphosis,  etc.);  a  careful  rater  training  was  also  performed  in  advance.  These  evaluations  were  used  for
describing the effect of treatments on the initially found SD on a Goal Attainment Scale (GAS T0-T1 and GAS T1-T2)
[15]. Briefly, GAS defines goals of treatment and describes their achievement on 5-point scale, in this case focusing on
the  number  of  identified  SD:  -2  (marked  worsening,  ≥50%),  -1  (mild  worsening,  <50%),  0  (unchanged),  +1  (mild
improvement, <50%), +2 (marked improvement, ≥50%). We chose to set the 0 goal to “unchanged” because of the
intrinsic progressing nature of ALS.
Sample Size and Statistical Analysis
Considering that patients with ALS might be especially fragile to manual therapies due to the important limb and
trunk weakness and to the respiratory insufficiency when in recumbent position, obliging to a continuous and careful
reassessment of the provided therapies,  we decided that  the presently reported sample size could be adequate for a
preliminary protocol, able to generate preliminary data on which grounding future studies.
Data are shown as mean ± standard deviation except where specifically noted. Statistical analysis was performed
with GraphPad Prism, version 4.00 program. Either, unpaired sample, or repeated measures Student’s t-test were used
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as appropriate and reported. Correlations were computed by the Pearson’s r test and differences between frequencies by
the χ2 test. Significance was set at p<0.05.
RESULTS
Osteopathic Characterization of ALS Patients
Demographic and clinical characteristics of the recruited patients are listed in Table 1. OMT allocated patients had
significantly faster DPI (more than two-fold), reflecting a tendency to more advanced diseases (lower scale scores) and
shorter disease durations. Bulbar onset patients were 2 in the OMT group and 1 in the FKT. Only one OMT patient had
PEG.
Table 1. Clinical and demographic data of the recruited patients at the different time points of the study.
Time x Treatment T0 x OMT
n=7
T0 x FKT
n=7
T1 x OMT
n=10
Age, yr 54.0 ± 11.6 51.0 ± 6.5 50.3 ± 7.9
Sex, M/F 5/2 5/2 8/2
Onset, Spinal/Bulbar 5/2 6/1 10/0
Duration, mo 17.1 ± 4.5
(11-25)
38.0 ± 30.5
(8-95)
35.6 ± 26.2
(13-98)
ALSFRS-R 35.0 ± 6.7
(28-46)
40.4 ± 4.0
(35-46)
33.9 ± 9.0
(16-46)
DPI 0.81 ± 0.47 *
(0.10-1.54)
0.32 ± 0.23
(0.04-0.62)
0.49 ± 0.39
(0.03-1.28)
ALSSS 29.5 ± 5.3
(24-37)
33.8 ± 2.7
(31-39)
30.6 ± 5.3
(21-38)
Norris 73.4 ± 16.9
(50-94)
90.0 ± 4.5
(85-98)
74.9 ± 19.7
(36-96)
Riluzole, Y/N 2/5 7/0 7/3
DPI, Disease Progression Index; FKT, usual care (physiotherapy); OMT, osteopathic manual treatment. Data are shown as mean ± SD. *p<0.05 vs.
FKT, two-tailed Student’s t-test.
At study entry (T0), a cervico-dorsal SD emerged as particularly prevalent in ALS patients, being documented in 11
(78%)  of  them and  only  in  4  (28%)  matched  healthy  controls  (χ2  7.04,  p<0.01,  OR 9.17,  95% CI  1.27-79.25).  No
correlation was found with clinical characteristics (disease duration, ALSFRS-R score, ALS-SS, Norris score, DPI,
prevalence of upper or lower motoneuron involvement), nor differences were found dichotomizing patients according
to: site of onset (spinal vs. bulbar), riluzole use or El Escorial category (probable vs. definite) (data not shown).
Table 2. McGill QoL total score, summary and macroarea scores did not vary significantly between groups and over time.
Mean ± SD (range).
Time T0 T1 T2
Treatment OMT
n=7
FKT
n=7
OMT
n=7
FKT
n=7
OMT
n=10
Total score 103.3 ± 24.6
(72-138)
103.3 ± 25.4
(53-126)
105.6 ± 26.5
(69-140)
106.0 ± 18.1
(86-128)
97.3 ± 22.4
(64-135)
Summary score 7.7 ± 1.9
(5-10)
6.9 ± 3.1
(0-10)
6.1 ± 2.6
(2-10)
7.0 ± 2.0
(5-9)
6.9 ± 1.9
(5-10)
Physical symptoms 19.7 ± 6.4
(11-28)
18.0 ± 7.5
(5-29)
21.1 ± 5.8
(10-28)
20.0 ± 8.7
(4-30)
20.8 ± 7.7
(8-30)
Psychological symptoms 17.1 ± 11.0
(3-31)
15.1 ± 8.4
(8-31)
14.0 ± 8.7
(3-28)
13.7 ± 5.3
(5-20)
17.0 ± 11.2
(2-34)
Physical well-being 7.6 ± 2.6
(2-10)
6.9 ± 1.6
(4-8)
6.0 ± 3.2
(2-10)
6.6 ± 1.9
(4-9)
7.1 ± 1.7
(4-10)
Psychological well-being 48.4 ± 9.2
(34-60)
43.0 ± 13.1
(15-53)
47.4 ± 10.9
(31-59)
46.0 ± 6.3
(38-55)
45.0 ± 7.6
(34-57)
Support 17.9 ± 2.1
(15-20)
16.6 ± 2.8
(13-20)
17.6 ± 3.0
(14-20)
17.0 ± 3.3
(11-20)
17.0 ± 2.7
(12-20)
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Primary Aims: Feasibility, Tolerability and Satisfaction
OMT was demonstrated feasible and safe over the whole study. All patients well adhered to treatment procedures.
No significant side effects were reported. Only one patient reported moderately increased pain the day after the first
treatment. New symptom onset was not recorded. Two OMT patients and two FKT ones dropped out at the end of T1
because of the impossibility of reaching treatment setting due to the advancing disease.
Overall OMT treated patients displayed high satisfaction with VAS scores of 8.34 ± 0.46 at T1 (n=7) and of 8.52 ±
0.60 at T2 (n=10); 5 patients enrolled in the FKT group specifically asked for entering in the OMT arm during the T1-
T2 period.
Secondary Aims: Pain, QoL and GAS
8 patients at T0 (57%) failed to report pain at the BPI, as well as 6 patients (43%) at T1 and 7 patients (50%) at T2.
Regarding the period T0-T1, no BPI differences were found between the two time points and the two groups (mean
delta  PSI:  -0.23  vs.  0.06,  for  OMT  and  FKT,  respectively;  mean  delta  PII:  0.71  vs.  1.48,  for  OMT  and  FKT,
respectively). On the other hand, considering the following period (T1-T2, n=10), a tendency toward pain reduction
over time was shown for PSI (p=0.05, two-tailed paired Student’s t-test; see Fig.  2),  which did not reach statistical
significance. In contrast, PII scores were unchanged (p=0.13; Fig. 2).
McGill  QoL  TS,  single  item  summary  score  and  macroareas  scores  did  not  significantly  change  over  time  or
between the two treatment groups (see Table 2).
Regarding blind osteopathic GAS scoring relative to the T0-T1 period, 3 patients (43%) allocated to OMT and 2
(28%) allocated to the FKT group showed a mild improvement (GAS score +1); none of the patients allocated to OMT
and 2 (28%) patients allocated to the FKT group worsened (GAS score -1) (χ2p=0.12). Regarding the T1-T2 period, one
patient (10%) mildly improved, while 3 patients (30%) mildly worsened in terms of number of SD; 6 patients (60%)
remained unchanged (GAS score 0; see Fig. 3).
Fig. (2). (A) Pain severity showed a tendency to decrease over time in ALS patients between T1 and T2 (PSI, pain severity index of
the BPI, p=0.05), while (B) interference with daily life activities was unchanged (PII, p=0.13). Two-tailed paired Student’s t-test;
mean ± SEM; n=10.
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DISCUSSION
In this pilot study OMT procedures were clearly found feasible and safe in ALS patients. Furthermore, OMT was
highly  satisfactory  for  these  patients.  Nevertheless,  no  differences  emerged  in  terms  of  secondary  aims,  i.e.,  the
efficiency in modifying pain and QoL, both between the two treatment arms for the first study period and over time.
Certainly, the limited sample size obliges to take these results cautiously since a tendency toward a reduction of the
severity index was shown over the second study period (T1-T2). Notably, OMT-allocated patients were generally more
severe and with shorter disease durations, underlying a significantly faster progression. This issue, unbalanced between
the two groups of patients due to the limited sample size, might have been reasonably contributing to the obtained lack
of significance and larger studies are needed to assess OMT effects on these selected outcomes.
Fig. (3). Goal attainment scale (GAS) in ALS patients undergoing to OMT or FKT during the first period (n=7 for each arm, T0-T1;
χ2p=0.12) and for those 10 patients completing the following two months (T1-T2 period).
Furthermore, BPI detects pain only over the last 24 hours, possibly not capturing the complexity of the relapsing-
remitting symptoms in a rapid progressing disease, such as ALS. Also, it is important to stress that several patients
reported that pain was not a major problem if compared to the decreasing functional autonomy. In order to overcome
this problem, previous attempts of detecting pain in ALS patients were done modifying the scale in order to refer to the
last week [1]. Possibly, ALS-dedicated pain questionnaires could be developed and validated in the future in order to
improve pain  detection.  Besides  “hard”  secondary  outcomes,  we decided to  include  a  single-blind  measure  able  to
describe putative treatment-induced modifications in terms of osteopathic medicine. To our knowledge, this is the first
attempt  of  blind  scoring  the  achievement  of  specific  osteopathic  outcomes  (in  this  case  SD  reduction)  by  using  a
patient-tailored  scale.  Goal  attainment  scaling  was  chosen,  setting  the  desired  expected  outcome  on  the  lack  of
osteopathic changes over time, considering the intrinsic worsening nature of ALS. Albeit no significant differences
were reported between OMT and FKT arms, a tendency toward less worsening was shown in the OMT group, again
suggesting that sample size could be increased before concluding. From our initial assessments, we conclude from this
pilot study that an osteopathic substrate for manual treatment might be present in ALS patients, since they express more
frequently a cervico-dorsal SD when compared to healthy matched controls. Albeit the significance of this dysfunction
in  terms  of  OMT  is  not  exactly  known,  future  studies  may  determine  if  this  SD  might  respond  to  focused  OMT
approaches and if this result might affect pain, QoL or other outcomes, for example functionally-related. We regard this
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approach as fully justified by the lack of current effective treatments able to contrast  disease-related pain and QoL
impairment in ALS patients. In fact, the high level of satisfaction perceived by all those patients receiving OMT raises
important questions related to what exactly is measured by the used outcomes. For example, we may postulate that the
lack of QoL improvement we observed in front of elevated VAS scores indicates that specific areas of one patient’s life
might selectively benefit from OMT. Nevertheless, considering that OMT could be adapted to each phase of the disease
and seems safe also in these fragile patients, we support the idea that could be an interesting option to explore in ALS.
In fact, a multimodal treatment strategy might help in developing approaches patient-tailored able to ease sufferance for
these individuals till the very end of their life, sustaining, at the same time, their caregivers.
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